Last reviewed · How we verify
ASTX727 LD
At a glance
| Generic name | ASTX727 LD |
|---|---|
| Also known as | oral decitabine (LD) + cedazuridine (E7727) |
| Sponsor | Taiho Oncology, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASTX727 LD CI brief — competitive landscape report
- ASTX727 LD updates RSS · CI watch RSS
- Taiho Oncology, Inc. portfolio CI